Redensyl: what is in it, and where the evidence comes from

What Redensyl is

Redensyl is a trademark held by Givaudan (the ingredient originated with Induchem). A 2025 review in the International Journal of Trichology sets out the composition, and it is a four-component blend:

• DHQG — dihydroquercetin-glucoside, described as sourced from larch tree and characterised as a stabilised polyphenol. Dihydroquercetin is more commonly known as taxifolin.
• EGCG2 — epigallocatechin-glucoside, a stabilised derivative of epigallocatechin gallate from green tea leaves.
• Glycine — the simplest amino acid, described in that review as a major component of keratin-associated proteins.
• Zinc — described as a cofactor for enzymes involved in incorporating cystine into keratin.

Note what that list is: two glycosylated flavonoid derivatives, one free amino acid, one mineral. Glycine is an amino acid, not a peptide — a peptide requires at least two residues joined by an amide bond. Nothing in Redensyl is a peptide, and any page describing it as a “peptide complex” is wrong on the chemistry.

Why the glucosides

Both polyphenols in the blend are described as stabilised derivatives, and that word is doing real work. Free flavonoids like taxifolin and epigallocatechin gallate are notoriously prone to oxidation and to browning in aqueous cosmetic systems, and epigallocatechin gallate in particular is unstable at neutral and alkaline pH. Glycosylation is the standard chemical answer: attach a sugar and you generally get better water solubility and better resistance to oxidation. That is the design logic, and it is also why the constituents in the blend are not interchangeable with the plain parent compounds bought separately.

Reference data

Redensyl has no molecular weight, no CAS number and no sequence, because it is a blend of four things. What can be given honestly is the identity data for the parent compounds of the two polyphenol constituents, plus glycine — and a clear statement of what is proprietary.

The ratios of the four components in the trade blend are proprietary and not published. That is worth stating plainly, because it is the reason no analytical certificate can confirm that a given drum of “Redensyl” is what it says it is in the way a certificate can for a single molecule.

The evidence, traced to its source

The proof-of-concept study is a technical file

The study behind Redensyl’s reputation — 26 men with grade 3–4 androgenetic alopecia, half receiving placebo and half receiving 3% Redensyl once daily for three months, with 85% of volunteers described as showing clinical improvement, an average +9% anagen hair, −17% telogen hair and +8% hair density corresponding to about 10,000 new hairs — comes from the Givaudan technical file dated 2014. The 2025 review cites it as exactly that, listing it among “technical files” reviewed alongside published papers.

Twenty-six men split into two arms is thirteen per arm. That is a pilot. It has not been peer-reviewed, it was run by the party that sells the material, and the striking “+10,000 hairs” figure is an extrapolation from a density percentage rather than a count. None of that makes it false; all of it makes it a supplier claim rather than a citation.

The one peer-reviewed randomised trial

Katoulis et al. (2020, Dermatol Ther) is a real randomised, single-blinded, vehicle-controlled study in 44 randomised patients with androgenetic alopecia, of whom 41 completed 24 weeks of twice-daily application; 26 received the active lotion. The median anagen-to-telogen ratio in the active group rose from 2.25 at baseline to 4.00 at 12 weeks and 6.02 at 24 weeks, and no significant adverse events were reported.

Two limitations belong with it, and the paper is open about the first. The lotion contained two patented formulas — Redensyl and Sepicontrol A5, a Cinnamomum bark extract — so the design cannot attribute the result to Redensyl. And it was single-blinded rather than double-blinded, on outcome measures that include clinical examination and self-assessment.

The rest

• Patel et al. (2025, Cureus) evaluated a branded serum containing Redensyl plus rice water extract, chia seed extract, rosemary oil and two further trade actives. It was open-label and single-arm with no control group, and was conducted by a contract research organisation for the brand. A single-arm open-label design cannot separate an ingredient effect from regression to the mean, seasonal variation or expectation.
• A widely quoted 106-man comparison of a Redensyl + Capixyl + Procapil combination against 5% minoxidil (Karaca and Akpolat, 2019) is not indexed in PubMed and tests three trade blends at once.
• The 2025 review’s own summary of this whole ingredient class: limited sample sizes, lack of comparison with standard therapies, non-uniformity between study groups, non-disclosure of the type of alopecia treated, and conflicts of interest.

Formulation and handling

• Water-soluble, and coloured. Glycosylated polyphenols are water-soluble by design. Polyphenols also carry colour and can darken over time and with pH, which is a finished-product aesthetics question as much as a stability one.
• Oxidation is the design problem. The glucosylation exists because the parent flavonoids oxidise readily. That does not make the derivatives inert — chelators and antioxidant systems remain a reasonable precaution — but no published stability window for the trade blend exists that we could find.
• Zinc plus polyphenol. Polyphenols chelate metals; the blend contains both a polyphenol and zinc by design, which means the supplier has already made choices about that interaction and adding further metal salts is not a neutral change.
• Supplied pre-diluted. The 1–3% use range refers to the trade liquid, not to any of the four components.

Verifying what you received

A four-component proprietary blend is the hardest case in this cluster to verify. There is no single expected mass for mass spectrometry to confirm and no single peak for HPLC to integrate as a purity figure. What a buyer can reasonably ask for is a certificate identifying the individual actives and confirming the absence of contaminants — and, realistically, a supplier relationship with traceability behind it.

That asymmetry is worth weighing against the ingredient’s appeal: single molecules such as Acetyl Tetrapeptide-3 can be proved to be what they claim to be, and a proprietary blend fundamentally cannot. See how to read a COA; batches we supply are on verify.

Sourcing and related ingredients

Supplied as raw material. Not supplied as a finished cosmetic, and no certificate is a cosmetic safety assessment.

Related: Capixyl is the other supplier-file-backed hair blend in this cluster and is frequently sold with it; Acetyl Tetrapeptide-3 is the defined peptide inside Capixyl. Everything in the cluster, with live availability, is on the cosmetic ingredient hub.

Frequently asked questions

Literature cited

1. Bikash C. “Topical Alternatives for Hair Loss: Beyond the Conventional.” Int J Trichology. 2025;17(1):13–19. PMID 40654553. pubmed.ncbi.nlm.nih.gov/40654553. (Constituents, 1–3% use range, and identification of the Givaudan technical file as the source of the 26-man figures.)
2. Givaudan. “Technical File Redensyl™.” 2014. A supplier document, not a peer-reviewed publication; cited here only as the traced origin of the widely-quoted 26-subject figures, per Bikash (2025).
3. Katoulis AC, Liakou AI, Koumaki D, et al. “A randomized, single-blinded, vehicle-controlled study of a topical active blend in the treatment of androgenetic alopecia.” Dermatol Ther. 2020;33(4):e13734. PMID 32473084. pubmed.ncbi.nlm.nih.gov/32473084. (44 randomised, 41 completed; lotion contained Redensyl and Sepicontrol A5.)
4. Patel M, Tuli N, Patel N, Merja A. “A Clinical Evaluation of the Safety, Efficacy, and Tolerability of the Soulflower Rosemary Redensyl Hair Growth Serum, Tetragain™, in Healthy Female Subjects for the Treatment of Alopecia.” Cureus. 2025;17(1):e77066. PMID 39917132. pubmed.ncbi.nlm.nih.gov/39917132. (Open-label, single-arm, no control; six-component product.)
5. Karaca N, Akpolat ND. “A comparative study between topical 5% minoxidil and topical ‘redensyl, capixyl, and procapil’ combination in men with androgenetic alopecia.” J Cosmo Trichol. 2019;5:140. Not indexed in PubMed; three trade blends tested together.
6. National Center for Biotechnology Information. “PubChem Compound Summary for CID 439533, Taxifolin.” pubchem.ncbi.nlm.nih.gov/compound/439533 (parent compound of DHQG).
7. National Center for Biotechnology Information. “PubChem Compound Summary for CID 65064, Epigallocatechin Gallate.” pubchem.ncbi.nlm.nih.gov/compound/65064 (parent compound of EGCG2).